Compare ADMA Biologics Inc (ADMA) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs National Beverage Corp. — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while National Beverage Corp. trades at $32.73 (market cap $3.04B). The key difference: National Beverage Corp. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADMA | FIZZ | |
|---|---|---|
Market Cap | $2.13B | $3.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $47.69 |
52-Week Low | $7.60 | $31.00 |
Enterprise Value | $2.20B | $2.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
FIZZ (National Beverage Corp.) trades at $32.48, down 2.55% today, with a bearish technical signal and mixed earnings performance. The company maintains strong profitability with 15.56% net margin and 34.03% ROE, though revenue has stagnated around $1.2B annually. Recent news highlights a special $3.25 dividend announcement that boosted shares despite three consecutive quarterly earnings misses.
Outlook remains cautious with 50% of analysts rating Sell amid competitive pressures and consumer weakness. The dividend provides shareholder return but earnings consistency remains a concern. Key risks include tariff impacts and market saturation, while current valuation multiples appear reasonable given profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
